A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

Background BI 836826 is a chimeric mouse–human monoclonal antibody directed against human CD37, a transmembrane protein expressed on mature B lymphocytes. This open-label, phase I dose-escalation trial (NCT02624492) was conducted to determine the maximum tolerated dose (MTD), safety/tolerability, an...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Invest New Drugs
Autors principals: Balzarotti, Monica, Magagnoli, Massimo, Canales, Miguel Ángel, Corradini, Paolo, Grande, Carlos, Sancho, Juan-Manuel, Zaja, Francesco, Quinson, Anne-Marie, Belsack, Valérie, Maier, Daniela, Carlo-Stella, Carmelo
Format: Artigo
Idioma:Inglês
Publicat: Springer US 2021
Matèries:
Phase I Studies
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8279964/
https://ncbi.nlm.nih.gov/pubmed/33523334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-01054-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars